Cenedella.de

Patient Advocate since 1977.


Leave a comment

Tommy Chong rumored to be re-appearing at ICBC Berlin

ICBC Berlin - The BERLIN PEACE ACCORDS...putting an end to the world war on Cannabis!

ICBC BERLIN will be held April 12-13, 2018 in Berlin Germany.

Tommy Chong and his CHONGS CHOICE offerings http://chongschoice.us/ were well-received by the international cannabis executives this year and rumor has it he will be there again in 2018.

For more information on this HIGHLY RECOMMENDED event, please go to:

http://internationalcbc.com/berlin-home/


Leave a comment

Canada expecting widespread shortage of cannabis within a year…exports expected to be impacted.

An official with a large Canadian producer of medical cannabis is confident consumers will be adequately supplied come next July, but says production will need to be increased.

“Right now, the existing capacity and what is already envisioned will not be sufficient to meet the needs of the adult consumer market,” Cam Battley, executive vice-president of Aurora Cannabis Inc., said in an interview Monday.

He has urged other companies to ramp up their production ahead of next July 1, when recreational marijuana is expected to be legalized.

“We need to expand our capacity right away simply to meet the demands of the rapidly growing medical cannabis system,” Battley said. “When the demand of the adult consumer system is layered on top of that, it’s a rush to build as much capacity as possible.”

Battley made the comments on the same day that Aurora began trading common shares on the Toronto Stock Exchange.

Alberta-based Aurora, one of several producers now listed on the TSX, is building what it describes as the world’s largest cannabis production facility at Edmonton International Airport.

Battley said Canada has a well-developed and successful medical cannabis system.

“This is a coming of age, not just for Aurora, but for the cannabis sector and what we’re seeing now is that Canada has established itself as the world leader in a brand new emerging industry that we are literally inventing in real time,” he said.

Battley added that officials from around the world have been coming to his facility in Alberta to visit and to learn how Canada has been so successful both on the medical side and on the consumer side.

Marijuana leaf Tweed

Health Canada says there are more than 60 authorized licensed producers of cannabis for medical purposes in Canada. (Photo courtesy of Allan Ziolkowski)

“There’s something very big happening and it’s a global movement and it is being led out of Canada.”

Jordan Sinclair, director of communications for Canopy Growth Corp., another major medical cannabis producer, agrees.

“There’s no doubt that we already are …that Canada is the global leader in cannabis on the medical side certainly,” he said.

“The demand doesn’t seem to be slowing down on the medical side of things and then with recreation, obviously that’s a massive market opportunity.”

Sinclair pointed out that Canopy, whose headquarters are in a former Hershey chocolate factory in Smiths Falls, southwest of Ottawa, was first listed on the big board of the TSX in July 2016.

“We’re very proud to have done that before anyone else in the country,” he added. “It does seem like now the pace is speeding up with other companies following in our footsteps (and) it signals that there is credibility across the sector.”

On its website, Health Canada says there are more than 52 authorized licensed producers of cannabis for medical purposes.

Ontario has issued 29 licences, followed by British Columbia with 12.

http://www.cbc.ca/beta/news/business/cannabis-consumer-demand-1.4219753?mc_cid=12994fc045&mc_eid=cd290ff91e


Leave a comment

BREAKING NEWS: GERMAN PHARMACIES SOLD OUT OF MEDICAL MARIJUANA….limited supply not available until September at the earliest.

The Cannabis Shortage Plaguing German Pharmacies

At present, Germany is experiencing massive delays in the delivery of medical cannabis. The supply at most pharmacies is limited to three or four of the 16 available medical strains. More than 10 of Germany’s medically-approved strains originate from the Canadian medical cannabis program, but currently, only smaller stocks of Pedanios’ 18/1 are available — the other five Pedanios Strains are sold out. None of the five strains produced by Tweed are available in German pharmacies.

Due to the lengthy import and export process, Canadian cannabis could return to the German market in September, at the earliest. Shortages from Canada are not the only problem, Dutch producer Bedrocan has not been able to deliver all of its six available medical strains.

On July 17th, medical patients in Germany reported that all wholesalers are currently sold out, posting on self-help network Cannabis as Medicine (SCM) and the German Hemp Federation’s (DHV) forums. Only a few pharmacies that pre-stocked the sought-after medicine can still provide for patients. Patients must, therefore, call their pharmacy before visiting the doctor, ask which of the few strains are available, and then request to have their medicine placed on hold. If a pharmacy can not fill the order of a prescribed strain, the patient’s prescription is effectively invalid. The patient then must revisit the doctor to obtain a valid prescription for an available strain.

The Number of German Patients Has Exploded

The current law for cannabis as medicine has been in existence for four months. In that time, the number of medical cannabis users has risen unpredictably fast. In the case of two of the largest health insurance companies, by mid-July, more than 3,100 patients had applied for reimbursement of medical cannabis prescribed by their doctor. The insurance company Techniker Krankenkasse (TK) published the only concrete figures on these applications.

According to the TK’s reports, 863 applications for reimbursement had been received by July 7, 522 of which were approved and 341 were rejected. Germany’s largest health insurance fund, the AOK, received roughly 2,300 applications by the same date but did not publish figures on approved or rejected applications.

The number of individuals who have applied for reimbursement from the two other large and numerous small insurance companies is not yet known. In view of the total number of insured persons in Germany, experts estimate there are several thousand unreported cases of pending reimbursement applications. In addition, there are no statistics available on patients who have received a cannabis prescription without applying for reimbursement. Maximilian Plenert, a member of the board of directors of the Federal Association for Accepting Drugs and Human Drug Policy (akzept.e.V.), was invited as an expert on medical cannabis to several German Bundestag hearings. On request from Marijuana.com, Plenert said he estimates that on the basis of the numbers and feedback received, about 10,000 patients have obtained medicinal cannabis flowers from pharmacies since the introduction of the law in March.

Due to these unforeseen developments, many cannabis patients are currently confronted with a shortage of supply. The German Hemp Association (DHV) has received numerous reports of affected patients who are currently waiting for their medicine. After all, those affected simply do not need “Cannabis Flos,” but one or more strain varieties, each with a specific active ingredient profile.

Currently, German patients are completely dependent on imported cannabis. They only receive what is not needed by the Dutch and Canadian cannabis programs. The imminent legalization in Canada will only exacerbate this problem, as bottlenecks are already expected in Canada by July 2018. In addition, it is far easier and less bureaucratic for Canadian producers to use the domestic recreational market instead of struggling with lengthy export- and import-licensing procedures.

The German Pharmacists Rejoice

While many health insurance companies continue to oppose cannabis for reasons beyond the exorbitant costs, pharmacists appear to be enjoying their new role. As the Deutsche Apotheker Zeitung reported recently, the majority of German pharmacies welcome the new law. Three out of ten pharmacists said the new law had a positive impact on the demand. However, the additional examination of the medicine represented a considerable effort, and 98 percent of pharmacists surveyed complained. This is probably why they charge almost 10 Euro per gram for the high effort of checking, repacking, and labeling cannabis medicine. The survey found that 30 percent of pharmacists have no opinion on the new regulations, while one in five oppose it.

Home Cultivation Remains a Political Issue

The production of medical cannabis in Germany could begin much faster if the licensing of the producers was a less bureaucratic than the current procedure. According to the recently founded Cannabis Agency, the earliest date to supply pharmacies with medicinal cannabis products is mid-2019. Allowing patients to grow cannabis could mitigate the problem of supply bottlenecks. But this solution, much like under ex-Premier Harper in Canada, is not politically viable in Germany. The federal government still carries out numerous trials against patients who have applied for the cultivation of a few plants to meet their medical needs. If the supply remains inadequate through 2019, the German Health Ministry will continue to losethese trials against cannabis patients.

Photo courtesy of Allie Beckett

ABOUT AUTHOR

Michael Knodt is an expert on cannabis politics and cannabis culture across Europe. Born in North Germany, Michael has been living in Berlin since 1990. He initially studied history and journalism before receiving his certification as a carpenter. Since then, Michael has made regular visits to countries where cannabis is cultivated, such as Jamaica and Morocco. He has worked as a freelancer for Weedmaps, Vice Magazine Germany, Sensi Seeds and numerous German-language cannabis magazines since 2004. From 2005 to 2013, Michael was the Editor-in-Chief of Germanys biggest cannabis periodical. He also is the face and presenter of the most popular program on cannabis prohibition and just launched a new channel called “DerMicha.” Aside from his journalistic work, Michael is a cannabis patient, activist, sought-after speaker on conferences and congresses, and a father of two.


Leave a comment

Isodiol and Canopy Growth sign agreement re: Pot.o.Coffee

Isodiol International Inc. Signs Definitive Licensing Agreement With Canopy Growth Corporation for Canadian and International Distribution

VANCOUVER, British Columbia, July 20, 2017 (GLOBE NEWSWIRE) — Isodiol International Inc. (CSE:ISOL) (OTC:LAGBF) (Frankfurt:LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has signed a licensing agreement with Canopy Growth Corporation (“Canopy”) (TSX:WEED) (https://www.canopygrowth.com). 

Canopy Growth is the world’s premier cannabis company that operates a collection of diverse brands and curated strain varieties, supported by over half a million square feet of indoor and greenhouse production capacity. Under this licensing agreement, Canopy Growth will have the right to manufacture and distribute the Company’s “Pot-O-Coffee” and “Pot-O-Tea” branded marijuana infused single serve K-Cup products in Canada and certain other markets internationally as federal regulations allow. Licensed products include caffeinated and de-caffeinated product lines as well as Isodiol’s single serve “Pot-O-Coco”. In addition to the Canadian rights, Canopy Growth shall have the right of first refusal to sell the “Pot-O” brand products in any territory outside of the US, Mexico and Puerto Rico.

“This distribution agreement has us positioned to increase our global footprint with the largest cannabis company in the world. We will continue to develop our Pot-O-Coffee product lines with ready to drink and cold brew products while working with Canopy Growth for international distribution channels. The Pot-O-Coffee brand is well recognized, and adding additional products to this line will continue to strengthen its market presence,” stated Isodiol’s CEO Marcos Agramont.

The availability of the various licensed products in Canada and elsewhere will differ depending on applicable laws and regulation. While Canadian law does not yet permit the manufacture and sale of marijuana infused products, the Company anticipates that such products will be permitted in the near future. Furthermore, currently proposed regulations which would permit the sale of infused products, would not allow such products to contain both marijuana and caffeine. As such, the specific product offerings in Canada and elsewhere may be limited. The Company will provide additional updates as regulations are adopted and as product roll-out plans are developed.

About Isodiol International Inc.

Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol’s nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin care products.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.


Leave a comment

Commentary about Western Europe – by Ben Ward CEO of Maricann – on CNBC

Forget the US. Here’s where medical marijuana is really taking off

  • There is a global shift in cannabis towards Western Europe.
  • That’s where the action in medical marijuana is really heating up.
  • Investor’s focused solely on the U.S. are missing the huge potential overseas.
Benjamin Ward, CEO of Maricann Group Inc.
58684301

David McNew | Getty Images

There’s a groundswell of support for cannabis legalisation in the United States, with 29 states, as well as Washington D.C. approved for medicinal cannabis, and eight for lifestyle use.

Things are farther ahead in Canada. Regulations for production and sales have been in place for over three years, and the federal government has introduced a timeline to full federal legalisation for lifestyle use in July 2018. Capacity in Canada for lifestyle alone is projected to reach “5 billion dollars per year to start,” according to a recent report from Deloitte.

Yet, while many investors focus on opportunities stemming from Canada’s upcoming legalization – plus the longer-term investment potential in what will likely be a growing number of American states – they are missing the global shift in cannabis towards Western Europe. That’s where the action is really heating up.

The population of the United States is approximately 325 million. There are 35 million living in Canada. But compare that to the European Union’s population of 510 million. Germany, with more than 80 million people alone, legalized medicinal cannabis in January of this year. Add that to Italy’s nascent existing medicinal cannabis program.

“European markets are increasingly important to the cannabis sector. Each has a well-funded medical system, residents who seek natural and complementary therapies, and a government-supported mandate to stop the rising tide of opiate addiction related to chronic pain treatment.”

These European markets are increasingly important to the cannabis sector. Each has a well-funded medical system, residents who seek natural and complementary therapies, and a government-supported mandate to stop the rising tide of opiate addiction related to chronic pain treatment.

Taken together, these and other European examples show that we’re seeing traditionally conservative attitudes shift as medicinal cannabis is legalized.

That also means investors in cannabis who focus solely on North America are missing the huge potential found across the Atlantic.

Those investors restricting their cannabis investments to this side of the ocean – and in the United States in particular – are left navigating an array of legislation on a state-by-state basis, prohibitive out-of-state investment regulations, and a prohibitive tax code. These investors miss the boat as they churn through such choppy water.

In Germany, cannabis will be produced by licenced producers and distributed to pharmacies like any other medication, with each prescription eligible for full reimbursement from health insurance.

In their patient-driven markets, Germans, Italians and other Europeans are demanding the alternative of cannabis over opiates.

In our view, people who think opiates are the only answer to pain relief have a similar mis-perception as people who still think medicinal cannabis is nothing more than smoking up with their doctor’s permission.

They are both wrong.

In short, medical cannabis is about personalized and effective medicine. It’s not about getting high.

The Europeans know that, as we do in North America.

As Germany moves smartly down this path of medicinal cannabis, the rest of Europe will soon follow. And to ignore 500 million people in a stable economy is a mistake.

We’re at the start of the global revolution. We all need to be looking to Europe next.

Commentary by Benjamin Ward, CEO of Maricann Group Inc., a vertically-integrated greenhouse producer and distributor of medical cannabis. Toronto, Canada-based Maricann is now building global teams in rapidly expanding European markets as well.

For more insight from CNBC contributors, follow @CNBCopinion on Twitter.


Leave a comment

Leafly Investigation: Why Are CBD Prices So Confusing?

Last summer I was hit with a nasty illness called gouty arthritis which caused my toes to swell to the size of gherkins. Walking was torture. Each step felt like a hot knife stabbing into the joints of my bloated digits. Even the weight of a single cotton sheet bearing down during sleep was unbearable.

Why the price disparity? Some products offer CBD at 5 cents per milligram. Others charge four to ten times as much.

I am an active, healthy man, but this condition left me feeling hobbled, unhappy and unfashionable. The only shoes I could comfortably wear were Birkenstocks, which just look wrong with a suit. I spent thousands of dollars on dozens of blood tests only to be told by the specialists at NYU’s Langone Medical Center that my best treatment option was Advil.

That was not a welcome prescription. Advil and other NSAID anti-inflammatories can, over time, can lead to damaged liver, kidneys, and, in extreme cases, death. An estimated 16,500 Americans die each year from complications related to these drugs.

The bigger problem for me was that NSAIDs offered spotty and unreliable relief.

So I looked into a cannabis-based solution.

On my next trip to Colorado, I bought some cannabidiol (CBD) tinctures, pills and salves. While CBD is no cure for arthritis—nothing can replace the joint lubricating synovial fluid once it diminishes—one 25 ml dose of tincture twice a day under the tongue, plus the occasional puff of CBD oil in a vape pen and the obligatory Omega 3 oils (which, I subsequently learned, optimize the cannabinoid receptors in the body) has noticeably reduced my pain. I am steadier on my feet and back in shoes.

RELATED STORY
CBD vs. THC: Why Is CBD Not Psychoactive?

But the fact is, when it comes to CBD medications I, like most patients, am groping in the dark. There are no reliable dosage guidelines for specific conditions, nor are there standard measurements, which is confusing when attempting to compare products. Most patients don’t understand which delivery system is optimal: Capsule? Tincture? Flower?

What’s more, the complete absence of federal safety regulations means the purity of CBD is always in question.

The most confusing and frustrating aspect, though, is the vast disparity in price. Some products offer CBD at 5 cents per milligram. Others charge four times as much—20 cents per mg. One company charges 60 cents per mg!

Here are the latest prices I could find online:

Consider this: Pine Tsunami, a low-THC (4.5%), high-CBD (15.3%) strain of cannabis flower, sells at Vela in Seattle for $184 an ounce. Chanel No.5 Grand Extrait perfume retails online for $276 an ounce. An ounce of HP printer ink goes for about $75 at Staples. A bar of .999 percent pure silver costs $18 an ounce. Most medicinal dried herbs retail for under $4 an ounce.

Pure CBD, at 10 cents per milligram, carries a consumer cost of $2,835 an ounce—more than twice that of pure gold.

If you scatter plot the prices of CBD for sale online, you get a sense of the helter-skelter nature of the market:

 

What gives? Are some producers turning this medicine into the “weed of greed? Or is the still-lingering weight of prohibition driving prices skyward?

As a journalist with piqued curiosity, and a patient seeking reliable medicine at a reasonable price, I decided to investigate.

Are some producers turning CBD into the ‘weed of greed’?

Hard to Know What You’re Getting

Even as public awareness of CBD’s healing potential has grown, it remains difficult to assess the quality, safety, and, importantly, the origin of most CBD products, thanks to the 80-year federal prohibition of cannabis and the resulting lack of both research and regulation.

“God knows what toxins are in the hemp processed in countries like China or Romania.”

Dr. Ethan Russo, leading cannabis researcher

Even though the law does not classify CBD as a Schedule I narcotic, the DEA claims that it is. (CBD, unlike THC, is not psychoactive.) That discrepancy leaves a lot of gray area when it comes to knowing how to operate. “It’s why some manufacturers don’t list CBD on the label,” says Heather Jackson, CEO and co-founder of Realm of Caring, a patient research and advocacy nonprofit in Colorado. “They may list ‘hemp extract,’ which is code for the entire cannabinoid content, but not necessarily CBD.”

Until recently, hemp growing and production was banned in the United States. As a result, much of the CBD being used today is extracted from hemp grown in Europe, or in some cases, China. (Google “CBD powder” and Alibaba and see what comes up.) This is troubling. Hemp has an extraordinary ability to absorb toxins from polluted soils—it’s a natural soil remediator. After the 1988 Chernobyl nuclear reactor meltdown, hemp was planted around the contaminated disaster site for exactly that reason. Oils extracted from plants grown near soils contaminated by pesticides or industrial effluents may contain those impurities in concentrated amounts. In today’s CBD market, manufacturers are under no obligation to tell consumers where their hemp was grown or to test it for contaminants.

Caveat emptor: Chinese-sourced CBD powder can be ordered in bulk for less than 2¢/mg on Alibaba.com.

“God knows what toxins are in the hemp processed in countries like China or Romania, which don’t have the same laws about pesticide use that we have,” says Dr. Ethan Russo, a neurologist, ethnobotanist, and one of America’s leading researchers into medical cannabis. “I don’t trust any of it and I don’t think anyone else should either.”

It’s a tough choice for patients: $200/month for CBD or $11/month for Advil.

The good news is that it’s increasingly possible to source higher-quality, laboratory-tested CBD derived from organic hemp grown in Western European countries—Austria, Germany, the Netherlands—with strong environmental regulations. High-quality hemp oils from Europe now wholesale for 0.5 cents to 1 cent per milligram. If encapsulating, bottling, and labeling that oil doubles the production cost, a manufacturer filling a pill bottle with 30 20-mg capsules (a standard dose) and selling that bottle online for $60 (8 cents/mg) is realizing at least a 400% markup. 

While that may suit American manufacturers, it’s challenging for financially strapped patients who must cough up $200 to $300 a month—the equivalent of a monthly car lease—for CBD meds. In a rational world, health insurance would cover much of that cost. But the federal government still refuses to treat cannabinoid medicine with any sort of rationality. For people on fixed or low incomes, CBD isn’t a sustainable option, especially compared to an NSAID like Advil, which clocks in at about 6 cents per pill, or about $11 per month.

Dr. Lester Grinspoon, the renowned Harvard psychiatrist who wrote the 1972 best seller Marihuana Reconsidereddubbed medical marijuana “the people’s medicine,” precisely because it could be made economically or grown at home. But at this price, CBD is more of a luxury product than an affordable treatment, less for the people and more for the pashas.

RELATED STORY
How to Assess THC and CBD Levels in Cannabis Strains and Products

The Price of Risk

I’m a patient, but I’m also a small business owner. I understand the challenge of conducting business in the cannabis space, which in many states is still considered a criminal activity. The media crows about “marijuana millionaires,” but the weight of prohibition can often be crushing to a small business with high startup costs, low revenue, and a fair amount of risk.

Federal law doesn’t directly address the status of CBD. But the DEA claims it’s illegal.

CBD producers shoulder a greater risk than the maker of any “normal channel” medicine. With the Trump administration sending mixed signals on hemp oil—the DEA’s notorious December 2016 Federal Register rule had manufacturers fretting that the government would ban it outright—the risk could suddenly turn hazardous.

Still, it’s difficult to fathom why CBD, derived from an easily grown and processed weed, is ten times more expensive than a precious metal.

RELATED STORY
New DEA Rule Says CBD Oil is Really, Truly, No-Joke Illegal

Is Green the New Silver?

Prohibition imposes a criminal risk factor, certainly. But cocaine carries a far greater risk factor than CBD. And at $100 per gram, cocaine sells for the same exact price—$2,835 per ounce. So legal risk can’t be the only reason.

As I asked industry manufacturers, retailers, consumers, and researchers to explain the high price of CBD, five answers were consistently floated: inefficient farming and production, the costs of introducing a new product into an unregulated market, insufficient consumer information, limited patient access, and greed.

RELATED STORY
Hold On! The DEA’s Move Against CBD May Not Be Legal

Wanted: Better Hemp Farming

Modern hemp farmers say that hemp cultivation methods in the United States are antiquated and inefficient. “Farmers spend way too much money using outdated methods on something which grows quite simply,” says Jacob Goldstein, co-founder of two-year-old Green Mountain CBD in Vermont.

Green Mountain CBD co-founders Jacob Goldstein, right, and Alejandro Bergad.

Goldstein, who counts Seventh Generation founder Alan Newmanas one of his primary investors, sells one of the lowest-cost CBD products on the market.

Growers “are cloning plants before transferring them to soil, which requires massive manpower and expensive real estate and can cost hundreds of thousands of dollars,” Goldstein told me. “We don’t do clones, so we don’t need $1000/square foot climate-controlled grow rooms and we don’t need all the manpower required to get them into the ground.”

Instead, Green Mountain breeds its own high-CBD seed crops indoors, which, Goldstein says, makes for stronger roots and heartier plants. Green Mountain then cultivates the plants on its small, 14-acre farm. Medical marijuana is legal in Vermont, so Green Mountain has fewer concerns about state law enforcement officials raiding the farm. Some hemp farmers in other states haven’t been so fortunate.

Other hemp producers use pricey extraction processes, often with harsh solvents such as butane or hexane that require further processing to remove. Green Mountain pares its costs by extracting with coconut oil, which Goldstein claims has the added benefit of enhancing the bioavailability of the CBD in each dose.

That all sounds good. But Green Mountain doesn’t employ scientists to test its products and guarantee consistent and reliable dosing. That may be another way to minimize production costs, but it means consumers are essentially trusting the Green Mountain brand to deliver the 600 mg of CBD it promises on the label—and deliver them without pesticide residues or other adulterants.

The Stanley Brothers’ CW Hemp Capsules.

CW Hemp, the Colorado makers of the oil that successfully treated Charlotte Figi, does test its products through a third-party lab. The company also has a staff microbiologist test regularly for molds and other microbes. CW Hemp’s revenues allow the company to voluntarily follow CGMP (Current Good Manufacturing Practice) methods, even though it’s not required. “That’s the gold standard, and it adds costs,” says Jesse Stanley, CW Hemp co-founder and vice president.

The company grows its own famously CBD-rich plants. Patients registered with Realm of Caring, the nonprofit group created by the Stanley brothers, can purchase its CBD oil in bulk for as little as 5 cents per milligram. If you’re not registered with Realm of Caring, CW Hemp will ship its CW Simply capsules anywhere in the United States for 6 cents per mg. It’s hard to know exactly what you’re getting, though, because CW Simply says each capsule contains 15mg of “Charlotte’s Web extract oil.” Does that mean each capsule contains 15mg of CBD? We’re meant to infer it, as Charlotte’s Web is synonymous with low-THC, high-CBD cannabis. But we can’t know for sure. The company may be skittish about actually listing CBD due to federal legal concerns—but that doesn’t do a patient any favors.

Brand Assurance

Green Mountain was founded about two years ago. The company sells its products exclusively online and does very little marketing. When I told a fellow patient about the company’s products, he was skeptical. “I’ve come to know and trust some of the pricier manufacturers precisely because they’ve invested millions in establishing that brand,” he said. “They’re less likely to cheat me, because they have more at stake.”

Well… possibly. It’s true that the costs of building a trustworthy brand, while unseen by consumers, are not insignificant. In an industry where the usual markers of quality assurance (FDA approval, state-mandated testing) simply don’t exist, brand equity becomes an important indicator of quality.

In the absence of an authority to police the brands, though, consumer awareness guarantees nothing. Reputations can be built on unsubstantiated claims. In 2015, the FDA tested 26 CBD products produced in California, Washington, and Arizona and discovered that many contained miniscule amounts of CBD—or none at all. One year later the FDA repeated the test on 22 CBD products from other states: same result.

RELATED STORY
The History and Emergence of the CBD Cannabis Strains

Botanical Bells and Whistles

Here’s another way to command a high price: Create sophisticated formulations, package them beautifully, and sell them for a premium. The beauty industry was built on this formula. Most of the $300 potions on the shelves at Sephora cost about $2 to make, according to Perry Romanowski. Romanowski is a cosmetic chemist and co-founder of BeautyBrains.com, a site that educates consumers about the science behind the cosmetic industry.

CBD companies know this strategy well.

“Not all CBD products are created equal,” says Kurt Forstmann, hemp category manager for Colorado-based Dixie Brands, one of America’s largest and best-known cannabis companies. “The vast majority are just squirting CBD in coconut oil and calling it medicine. Our products have synergistic ingredients that potentiate the medicinal qualities, and many of them are as expensive as CBD.”

Dixie’s Aceso brand: CBD only, in a beverage powder.

A year and a half ago, Dixie created the Aceso brand, which offers THC-free CBD products to consumers around the country, regardless of the legal status of their state. Aceso’s “Calm” formulationcombines L-theanine (a Green Tea extract), plus two pharmaceutical-grade terpenes: linalool, which is found in lavender; and limonene from grapefruit. It’s packaged as a beverage powder, with 7.5 mg of CBD per sachet, at a price of 22 cents per mg. (The company’s CBD capsules, offered under the Dixie Botanicals brand, offer CBD at about 20 cents per mg.)

Aceso Calm certainly smells luxurious. But are those terpenes an integral part of a medically effective entourage effect, working in harmony with the CBD—or do they just please the olfactory sense? They jury’s still out, again, due to the lack of scientific studies. We do know one thing for sure: The addition of terpenes do enhance the cost.

Even if those supplementary ingredients equal the costs of CBD, though, Dixie’s products are still three to four times the price of Green Mountain’s. To give Dixie its due, the company spends a lot of money double-testing every batch of imported CBD oil for heavy metals, pesticides, microbes, and solvents—once when the oil arrives at their facility, and again after the final product is assembled. “We don’t trust anyone in this business,” Forstmann says.

RELATED STORY
Terpenes: The Flavors of Cannabis Aromatherapy

Hemp-Sourced Vs. Cannabis-Sourced

Another way of judging the value of hemp-derived CBD is to compare it to the CBD extracted from more expensive cannabis flowers.

Unlike the other manufacturers surveyed in this article, Aunt Zelda’s, a small patient collective based in Bodega Bay, CA, makes its CBD tinctures and balms using cannabis flower, which is usually about two to four times more expensive than hemp. Their CBD oils, which are typically blended with THC, cost 2.25 cents per mg to manufacture, and that cost includes lab testing, tinted bottles, packaging, compliance, labor, rent, and utilities.

Unlike most CBD manufacturers, Aunt Zelda’s posts its independent lab test results online. A 600-mg bottle of their CBD-THC oil costs $13.50 to produce. It wholesales for $27. California distributors tack on another 30%, which ratchets the price up to $34. Dispensaries double that—a typical markup in any retail business—to about $70.

RELATED STORY
Cannabis’s Entourage Effect: Why Whole Plant Medicine Matters

Aunt Zelda’s delivers CBD to the patient at 11.6 cents per mg—but only in California. Because their oils contain more than 0.3% THC, they sell only to authorized California medical cannabis patients. And it’s not easy for patients to find; retail partners listed on Zelda’s website do not actually list Zelda’s CBD on their own menus. Aunt Zelda’s might make some of the highest-quality CBD in America, but it’s extremely difficult for most patients buy.

Today’s CBD market is young and unnaturally warped by prohibition. As it matures, prices will stabilize—and hopefully decline.

Aunt Zelda’s is a nonprofit patient-based service. Revenue is important, but it’s not the sole driver of the operation. That raises a question. If Zelda’s meticulously crafted, high-end cannabis-sourced product sells for 11.6 cents per mg, how can a bottle of CBD tincture made from cheap imported hemp oil, of unknown quality and purity, sell online for two to five times the price?

The answer can be found in a complicated mix of factors. Today’s CBD market is young. Four years ago it was practically nonexistent. It’s also unnaturally warped by cannabis prohibition, legal uncertainties, the absence of FDA regulations, and insufficient consumer information and access. Some companies are producing high-quality, locally sourced, lab-tested, and toxin-free CBD. Others are importing cheap hemp oil of unknown quality and slapping a CBD label on a bottle. It’s extremely difficult for patients to know the difference. Aunt Zelda’s produces excellent CBD guaranteed by lab results—but almost nobody outside California can buy it.

Manufacturers are rushing in with products and tossing out prices to see what sticks. If you believe in market efficiency, a middle price zone will eventually emerge when today’s massive inefficiencies subside. Companies will learn how to increase their quality and decrease their prices and still turn a profit.

That occurs, however, only when markets mature. Right now, “there are a lot of snake oil salesman trying to profit off people in need,” Jesse Stanley told me. “It’s unfortunate, but those dynamics are very real.” In the long run, though, Stanley believes the scamsters and low-quality manufacturers will be driven out, and the promise of this theoretically affordable plant-based medicine will have its due. “CBD is a new product that is revolutionizing the way we treat disease,” he said, “and I think we’ll see amazing things in the future.”

Gordon Baker, a medical cannabis researcher and patient advocate, contributed to this report.


Leave a comment

Dutch Cannabis Social Club Applies for Legal Cannabis Cultivation – by Michal Knodt

Dutch Cannabis Social Club Applies for Legal Cannabis Cultivation

The Tree of Life, Amsterdam’s first and only cannabis social club, recently filed a request for an exemption from the Dutch Opium Act to the Ministry of Health, Welfare and Sport. The club applied to grow cannabis for scientific research purposes. The association of recreational and medical users believes this can be accomplished in compliance with the Opium Act because the law states that the production of narcotics can be allowed for “medical and scientific purposes.”

“We want to study the needs of users as they know the composition of cannabis due to it is being listed and labeled,” club president Rosaria Ricci told the Dutch media. “The research is aimed to document the health of its (the club’s) members. We are also curious about the effects of controlled cultivation.”

“Those terms are not defined,” said the club’s legal adviser, Kaj Hollemans. “There is room for interpretation.”

Born Out of Necessity

In 2017, the coffeeshop culture of Amsterdam is merely a shadow of its former glory. Due to numerous toughened rules enacted during the last two decades, Amsterdam’s 1,000 coffeeshops have dwindled to about 200. Due to a lack of competition, prices are often high, and the quality is hit or miss given missing regulatory controls. The reason for Amsterdam’s decline is cannabis-hostile federal governments, which have been in power since 2002. Some members of the country’s conservative political parties, VVD Volkspartij voor Vrijheid en Democratie) or CDA (Christen Democratisch Appèl), would prefer to close down all coffeeshops which have been tolerated since the 1970s and long since established in Dutch culture. The VVD- or CDA-dominated governments have constantly tightened the rules for operators and visitors since the turn of the century. A THC maximum of 15%, the constant tightening of the distance rule to schools, a smoking ban in many coffeeshops, and the reduction of the maximum output to five grams are only the most drastic limitations that cannaseurs have endured in the Netherlands. In order to keep away the so-called “drug-tourists,” politicians decided to introduce a buyers-ID for local residents in the southern border regions in 2012. The so-called “Wietpas,” however, was abolished once the cannabis buying scene increasingly shifted to the illegal street dealers. It also spoiled other businesses profiting from the vivid coffeeshop tourism on the borders of Belgium and Germany. In 2008, the coffeeshop trade union (Bond Van Cannabis Detaillisten-BCD) announced that coffeeshop tourists not only invest money in flowers or hash but also in the neighboring infrastructure and surrounding businesses. Regardless of their expenses for cannabis products, due to the BCD in Maastricht, coffeeshop tourists spend between 140 and 170 million Euro in the town annually.

While tourists suffer slightly from the current situation, Dutch consumers have been hit particularly hard. On the one hand, you can buy cannabis in every town, and on the other hand, even the cultivation of up to five plants for one’s personal use is hardly tolerated indoors anymore because the cultivation under artificial light is now generally regarded as a professional operation. Outdoor cultivation of up to five plants is only tolerated when it is not in public view and others do not feel bothered by its presence. Back in 2015, a new growshop law led to the fact that many of the oldest grow shops in the world have either voluntarily close or banished every product related to cannabis, acting as “Hydro” or “Urban gardening-shops” now. While lamps and other equipment are still legal, consulting about cannabis, seeds, growing guides or cannabis magazines has been strictly forbidden in Dutch growshops since 2015.

The Tree of Life: Self Supplied Since 2014

After the quality of cannabis had sunk to new lows for the locals three years ago, 36 cannaseurs joined together in Amsterdam to found the Tree of Life, the first cannabis social club in the Netherlands. At that time, the club’s founding members hoped to enjoy a similar toleration status as the regions’ coffeeshops. The minimum age for members is 21-years-old, with the memberships granted exclusively given to Netherlands residents. Medical patients with a valid prescription may join when they turn 18. The financial report of the club is available to all members at all times. The Amsterdam Mayor van der Laan supported the idea of the club, and initially, the newly founded club was able to act without any interference. The club grows a maximum of five plants for each club member, using neither pesticides nor insecticides. Interested members may take a look at the production site at this time. Just as in the Dutch coffeeshops, the maximum dose is five grams per day, per person, though patients with the appropriate prescription may purchase more. New members are asked about their consumption habits when they enter so that cultivation can be planned accordingly. The gardeners always produce a slight surplus so that bad harvests, pests, or human failure are not detrimental.

In the beginning, the weekly meetings of the club took place in a cozy café where members were given their weekly or monthly allotment of cannabis. A few months after the club’s foundation, the first press reports were published and club president Rosaria Ricci remained confident about not being bothered by the prosecutor’s office. After all, their club was more strict than any coffeeshop in the city and operated without any profits. But in February 2015, the club received a letter from the public prosecutor’s office, which clearly excluded the social club model from toleration. The main reason behind the decision was that the number of five plants tolerated in the Netherlands was being exceeded. If the club continued to operate in public, it had to expect repressive measures. According to this announcement, the Tree of Life was forced to either dissolve or simply give up its common goal of community cultivation. But the members did not want to accept either outcome and decided to change their fundamental strategy. No longer satisfied with the club’s goal of effective toleration, their goal was to grow 100% legal cannabis.

Solid Scientific Background

The Amsterdam Social Club decided to develop a scientific research program on the effects of controlled growing on responsible adult cannabis users. This program enables consumers to rely on accurate information about the growing process, the quality, as well as the chemistry of the cannabis, which will be produced exclusively for the members of the association. “We are also excited to do research on strains and on how we can better classify them based on the chemical analysis and based on members feedback,” the club’s president Rosaria Ricci told Marijuana.com. The research plan was set up in cooperation with the University of Amsterdam (UvA, Institute of Criminology) and the Amsterdam Medical Centre (AMC). Finally, the application for scientific research based on a special exemption from the Dutch Opium Law by the ministry of Public Health was issued at the beginning of July.

“It is important to stress the impact that our experiment could have in other European countries, if successful. It would be a legal alternative to other models still operating in a gray area, like coffeeshops or other Spanish, Belgian cannabis Social Clubs,“ Ricci explained. “We, as Tree of Life, have probably chosen the most difficult way, but this way would make it possible to operate according to high quality standards from the very beginning and give the guarantee of product quality to our members.“

Whether or not it will succeed is still quite uncertain. Despite the fact that cannabis policy is officially a health item in the Netherlands, basic decisions about cannabis policies are still being drawn by the Dutch Ministry of Justice, and not the Dutch Ministry of Health.

Photo courtesy of Allie Beckett